Business Description
Valion Bio Inc
NAICS : 541714
SIC : 2834
ISIN : US8887053085
Total Employee Number:
52Description
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.42 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 1.54 | |||||
Debt-to-EBITDA | -1.45 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -2.97 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 84 | |||||
3-Year EPS without NRI Growth Rate | 84.2 | |||||
3-Year FCF Growth Rate | 83.6 | |||||
3-Year Book Growth Rate | -77.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.4 | |||||
9-Day RSI | 29.02 | |||||
14-Day RSI | 32.39 | |||||
3-1 Month Momentum % | -39.14 | |||||
6-1 Month Momentum % | -54.72 | |||||
12-1 Month Momentum % | -86.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.31 | |||||
Quick Ratio | 3.02 | |||||
Cash Ratio | 2.76 | |||||
Days Inventory | 379.41 | |||||
Days Payable | 458.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -649.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 561.43 | |||||
Operating Margin % | 17180 | |||||
Net Margin % | 19397.14 | |||||
EBITDA Margin % | 16761.43 | |||||
FCF Margin % | 15975.71 | |||||
OCF Margin % | 15887.14 | |||||
ROE % | -168.99 | |||||
ROA % | -80.5 | |||||
ROIC % | -106.37 | |||||
3-Year ROIIC % | 12.31 | |||||
ROC (Joel Greenblatt) % | -152.49 | |||||
ROCE % | -75.55 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 4.86 | |||||
PB Ratio | 0.11 | |||||
Price-to-Tangible-Book | 0.23 | |||||
EV-to-EBIT | -0.94 | |||||
EV-to-EBITDA | -0.96 | |||||
EV-to-Revenue | -160.09 | |||||
EV-to-Forward-Revenue | 0.42 | |||||
EV-to-FCF | -1 | |||||
Earnings Yield (Greenblatt) % | -106.38 | |||||
FCF Yield % | -806.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Valion Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | -0.07 | ||
| EPS (TTM) ($) | -7.529 | ||
| Beta | 1.527 | ||
| 3-Year Sharpe Ratio | -1.03 | ||
| 3-Year Sortino Ratio | -1.31 | ||
| Volatility % | 47.16 | ||
| 14-Day RSI | 32.39 | ||
| 14-Day ATR ($) | 0.075005 | ||
| 20-Day SMA ($) | 0.525545 | ||
| 12-1 Month Momentum % | -86.06 | ||
| 52-Week Range ($) | 0.3999 - 5.6 | ||
| Shares Outstanding (Mil) | 3.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Valion Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Valion Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 122 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 121 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 16:30 | In 31 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 30 days | ||
| General meeting for 2026 | 2026-06-30 13:00 | 0.55 (+1.85%) | ||
| General meeting for 2026 | 2026-05-28 10:00 | 0.88 (+3.60%) | ||
| First quarter earnings conference call for 2026 | 2026-05-15 16:30 | 0.93 (-3.04%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.93 (-3.04%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 16:30 | 0.97 (-9.53%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.97 (-9.53%) |
Show
Entries
Valion Bio Inc Frequently Asked Questions
What is Valion Bio Inc(VBIO)'s stock price today?
The current price of VBIO is $0.43. The 52 week high of VBIO is $5.60 and 52 week low is $0.40.
When is next earnings date of Valion Bio Inc(VBIO)?
The next earnings date of Valion Bio Inc(VBIO) is 2026-08-14 Est..
Does Valion Bio Inc(VBIO) pay dividends? If so, how much?
Valion Bio Inc(VBIO) does not pay dividend.
Guru Commentaries on NAS:VBIO
No articles.
Press Release
Articles on Valion Bio Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers